Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib ― a retrospective chart review analysisGRIFFIN, James D; GUERIN, Annie; LEI CHEN et al.Current medical research and opinion. 2013, Vol 29, Num 6, pp 623-631, issn 0300-7995, 9 p.Article

Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinibGOLDBERG, Stuart L; LEI CHEN; GUERIN, Annie et al.Current medical research and opinion. 2013, Vol 29, Num 9, pp 1075-1082, issn 0300-7995, 8 p.Article